AbbVie (ABBV) Stock Forecast & Price Target

Compare

23,267 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABBV Analyst Ratings

Moderate Buy

14 Buy

9 Hold

0 Sell

Based on 23 analysts giving stock ratings to

AbbVie

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABBV Stock 12 Month Forecast

Average Price Target

$245.00

▲(11.79% Upside)

Based on 23 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $245.00 with a high forecast of $289.00 and a low forecast of $203.00. The average price target represents a 11.79% change from the last price of $219.16.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"170":"$170","200":"$200","230":"$230","260":"$260","290":"$290"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":289,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$289.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":245,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$245.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":203,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$203.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[170,200,230,260,290],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,218.04,223.49846153846153,228.95692307692306,234.4153846153846,239.87384615384616,245.3323076923077,250.79076923076923,256.24923076923073,261.7076923076923,267.16615384615386,272.62461538461537,278.08307692307693,283.5415384615385,{"y":289,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,218.04,220.11384615384614,222.1876923076923,224.26153846153846,226.3353846153846,228.40923076923076,230.4830769230769,232.55692307692308,234.63076923076923,236.70461538461538,238.77846153846153,240.8523076923077,242.92615384615385,{"y":245,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,218.04,216.8830769230769,215.72615384615384,214.56923076923076,213.41230769230768,212.2553846153846,211.09846153846152,209.94153846153847,208.7846153846154,207.6276923076923,206.47076923076924,205.31384615384616,204.15692307692308,{"y":203,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":196.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.63,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.87,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":193.82,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":242.63,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":218.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$289.00

Average Price Target$245.00

Lowest Price Target$203.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Trung Huynh

UBS

$195→$220

Hold

0.38%

Upside

Reiterated

11/07/25

AbbVie price target raised to $220 from $195 at UBSAbbVie price target raised to $220 from $195 at UBS

Veda Pharmyne

TR | OpenAI - 4o

$228→$229

Hold

4.49%

Upside

Reiterated

11/05/25

AI Generated ArticleAI Generated Article

David Amsellem

Piper Sandler

$284→$289

Buy

31.87%

Upside

Reiterated

11/05/25

AbbVie price target raised to $289 from $284 at Piper SandlerAbbVie price target raised to $289 from $284 at Piper Sandler

Elmar Kraus

DZ BANK AG

$237

Hold

8.14%

Upside

Downgraded

11/04/25

AbbVie downgraded to Hold from Buy at DZ BankAbbVie downgraded to Hold from Buy at DZ Bank

Tim Anderson

Bank of America Securities

$251→$248

Hold

13.16%

Upside

Reiterated

11/03/25

AbbVie price target lowered to $248 from $251 at BofAAbbVie price target lowered to $248 from $251 at BofA

Mohit Bansal

Wells Fargo

$260

Buy

18.63%

Upside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Merus (NASDAQ: MRUS)

Geoff Meacham

Citi

$240→$235

Hold

7.23%

Upside

Reiterated

11/03/25

AbbVie price target lowered to $235 from $240 at CitiAbbVie price target lowered to $235 from $240 at Citi

Evan Seigerman

BMO Capital

$240→$258

Buy

17.72%

Upside

Reiterated

11/03/25

AbbVie (ABBV) Receives a Buy from BMO CapitalPost 3Q25: Close Shaves in I&I and Aesthetic Headaches Raise Questions

Chris Schott

J.P. Morgan

$250→$260

Buy

18.63%

Upside

Reiterated

11/03/25

AbbVie price target raised to $260 from $250 at JPMorganAbbVie price target raised to $260 from $250 at JPMorgan

Steve Scala

TD Cowen

$280

Buy

27.76%

Upside

Reiterated

10/31/25

TD Cowen Remains a Buy on AbbVie (ABBV)

Terence Flynn

Morgan Stanley

$255→$261

Buy

19.09%

Upside

Reiterated

10/31/25

AbbVie price target raised to $261 from $255 at Morgan StanleyAbbVie price target raised to $261 from $255 at Morgan Stanley

Matt Phipps

William Blair

―

Buy

―

Reiterated

10/31/25

AbbVie's Strong Financial Performance and Growth Potential Justifies Buy Rating

Luisa Hector

Berenberg Bank

$270

Buy

23.20%

Upside

Reiterated

10/27/25

AbbVie (ABBV) Receives a Buy from Berenberg Bank

Asad Haider

Goldman Sachs

$217→$218

Hold

-0.53%

Downside

Reiterated

10/23/25

AbbVie Hold Rating: Balancing Strong Performance with Emerging Challenges

Courtney Breen

Bernstein

$203

Hold

-7.37%

Downside

Assigned

10/21/25

Bernstein Sticks to Its Hold Rating for AbbVie (ABBV)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Trung Huynh

UBS

$195→$220

Hold

0.38%

Upside

Reiterated

11/07/25

AbbVie price target raised to $220 from $195 at UBSAbbVie price target raised to $220 from $195 at UBS

Veda Pharmyne

TR | OpenAI - 4o

$228→$229

Hold

4.49%

Upside

Reiterated

11/05/25

AI Generated ArticleAI Generated Article

David Amsellem

Piper Sandler

$284→$289

Buy

31.87%

Upside

Reiterated

11/05/25

AbbVie price target raised to $289 from $284 at Piper SandlerAbbVie price target raised to $289 from $284 at Piper Sandler

Elmar Kraus

DZ BANK AG

$237

Hold

8.14%

Upside

Downgraded

11/04/25

AbbVie downgraded to Hold from Buy at DZ BankAbbVie downgraded to Hold from Buy at DZ Bank

Tim Anderson

Bank of America Securities

$251→$248

Hold

13.16%

Upside

Reiterated

11/03/25

AbbVie price target lowered to $248 from $251 at BofAAbbVie price target lowered to $248 from $251 at BofA

Mohit Bansal

Wells Fargo

$260

Buy

18.63%

Upside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Merus (NASDAQ: MRUS)

Geoff Meacham

Citi

$240→$235

Hold

7.23%

Upside

Reiterated

11/03/25

AbbVie price target lowered to $235 from $240 at CitiAbbVie price target lowered to $235 from $240 at Citi

Evan Seigerman

BMO Capital

$240→$258

Buy

17.72%

Upside

Reiterated

11/03/25

AbbVie (ABBV) Receives a Buy from BMO CapitalPost 3Q25: Close Shaves in I&I and Aesthetic Headaches Raise Questions

Chris Schott

J.P. Morgan

$250→$260

Buy

18.63%

Upside

Reiterated

11/03/25

AbbVie price target raised to $260 from $250 at JPMorganAbbVie price target raised to $260 from $250 at JPMorgan

Steve Scala

TD Cowen

$280

Buy

27.76%

Upside

Reiterated

10/31/25

TD Cowen Remains a Buy on AbbVie (ABBV)

Terence Flynn

Morgan Stanley

$255→$261

Buy

19.09%

Upside

Reiterated

10/31/25

AbbVie price target raised to $261 from $255 at Morgan StanleyAbbVie price target raised to $261 from $255 at Morgan Stanley

Matt Phipps

William Blair

―

Buy

―

Reiterated

10/31/25

AbbVie's Strong Financial Performance and Growth Potential Justifies Buy Rating

Luisa Hector

Berenberg Bank

$270

Buy

23.20%

Upside

Reiterated

10/27/25

AbbVie (ABBV) Receives a Buy from Berenberg Bank

Asad Haider

Goldman Sachs

$217→$218

Hold

-0.53%

Downside

Reiterated

10/23/25

AbbVie Hold Rating: Balancing Strong Performance with Emerging Challenges

Courtney Breen

Bernstein

$203

Hold

-7.37%

Downside

Assigned

10/21/25

Bernstein Sticks to Its Hold Rating for AbbVie (ABBV)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

1 Month

xxx

Success Rate

11/15 ratings generated profit

Average Return

+4.31%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +4.31% per trade.

3 Months

xxx

Success Rate

18/24 ratings generated profit

Average Return

+7.60%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +7.60% per trade.

1 Year

Evan SeigermanBMO Capital

Success Rate

17/17 ratings generated profit

Average Return

+21.06%

reiterated a buy rating 7 days ago

Copying Evan Seigerman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +21.06% per trade.

2 Years

xxx

Success Rate

24/24 ratings generated profit

Average Return

+34.52%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +34.52% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABBV Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABBV has received 31 Buy Ratings, 20 Hold Ratings, and 0 Sell Ratings. ABBV average Analyst price target in the past 3 months is 245.00.

Each month's total comprises the sum of three months' worth of ratings.

ABBV Financial Forecast

ABBV Earnings Forecast

Next quarter’s earnings estimate for ABBV is $3.36 with a range of $3.31 to $3.54. The previous quarter’s EPS was $1.86. ABBV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ABBV has Preformed in-line its overall industry.

ABBV Sales Forecast

Next quarter’s sales forecast for ABBV is $16.34B with a range of $16.23B to $16.58B. The previous quarter’s sales results were $15.78B. ABBV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ABBV has Preformed in-line its overall industry.

ABBV Stock Forecast FAQ

What is ABBV’s average 12-month price target, according to analysts?

Based on analyst ratings, AbbVie’s 12-month average price target is 245.00.

What is ABBV’s upside potential, based on the analysts’ average price target?

AbbVie has 11.79% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ABBV a Buy, Sell or Hold?

AbbVie has a consensus rating of Moderate Buy which is based on 14 buy ratings, 9 hold ratings and 0 sell ratings.

What is AbbVie’s price target?

The average price target for AbbVie is 245.00. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $289.00 ,the lowest forecast is $203.00. The average price target represents 11.79% Increase from the current price of $219.16.

What do analysts say about AbbVie?

AbbVie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of ABBV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

AbbVie (ABBV) Stock Forecast & Price Target

ABBV Analyst Ratings

ABBV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AbbVie

ABBV Analyst Recommendation Trends

ABBV Financial Forecast

ABBV Earnings Forecast

ABBV Sales Forecast

ABBV Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts